A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

A Multicenter, Double Arms, Prospective Phase 4 Study to Evaluating the Efficacy and Safety of Combination Therapy of PAD Versus VCD Treatment in Previously Untreated Subjects With Multiple Myeloma.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01868828
• Other study ID #: PAD VS VCD Clinical Protocol
• Status: Recruiting
• Phase: Phase 4
• First received: May 22, 2013
• Last updated: June 4, 2013
• Start date: May 2013
• Est. completion date: May 2017

Study information

• Verified date: June 2013
• Source: Peking University People's Hospital
• Contact: Jin Lu, PhD
• Email: onco_velcade123[@]163.com
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

A multicenter, double arms, prospective randomized controlled phase 4 study. Approximately 50 previously untreated subjects with multiple myeloma will be enrolled. The study will consist of 6 phases, screening, treatment and follow-up.

Description:

Screening

At the screening visit, informed consent will be obtained from all subjects who are deemed potentially eligible for enrollment in the study, according to the protocol-specified inclusion and exclusion criteria.

Treatment

Eligible patients are randomly assigned to receive either treatment PAD or VCD. All eligible subjects will be evaluated after 4 cycles treatment. According to the assessment of researchers and the willingness of patients to decide whether to autologous stem-cell transplantation (ASCT). Suitable for transplant patients will accept hematopoietic stem cell transplantation. Not suitable for transplant patients will continue accept treatment for 8 cycles. The patients who accept more than 4 cycles treatment will receive efficacy evaluation.

Follow-up

All patients will receive 12 months of follow-up after the treatment period. Follow-up at 4, 6, 8 and 12 month after the treatment period respectively. Subjects who have disease progression or accept other resistance myeloma therapy during the 12 months of follow-up phase will stop assessed about the study and start followed up only for survival status every 6 months through telephone interviews or to research center follow-up. All patients will accept the follow-up for survival until last case patient who complete follow-up.

Safety will be evaluated throughout the study by assessment of adverse events (AEs), physical examination, vital signs and clinical laboratory findings.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: May 2017
• Est. primary completion date: May 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 65 Years

Eligibility

Inclusion Criteria:

1. Men or women aged <65 years.

2. Previously untreated subjects with multiple myeloma.

3. No clinically significant cardiac amyloidosis (Echocardiography septal=10mm, brain natriuretic peptide (BNP) < 500).

4. Pulmonary infection (if any) must be controlled effectively.

5. Chronic viral hepatitis (if any) must be controlled effectively.(Subjects with HBs Ag positive need to monitor hepatitis B virus-DNA (HBV-DNA )quantitative test regularly);

6. Liver function (aminotransferase, bilirubin)?2 x the upper limit of normal (ULN).

7. Expected lifetime More than 3 months.

8. Be able to read and sign (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.

Exclusion Criteria:

1. Patients with relapsed multiple myeloma.

2. Need to change the program according to the researchers' evaluated patients with disease progression during treatment.

3. Had uncontrolled or severe cardiovascular disease. Had a myocardial infarction within 6 months of enrolment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis.

4. Has a history of allergic reaction to compounds containing boron or mannitol.

5. Severe neuropathy may affect the treatment, according to the researchers to determine.

6. According to the program or the investigator's judgment, the patient is suffering from a serious physical illness or mental illness may interfere with participation in this clinical study.

7. Concurrent treatment with another investigational agent.

8. Pregnant or breast-feeding women.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• PAD
Induction Therapy of PAD for 4 cycles.
• VCD
Induction Therapy of VCD for 4 cycles.

Other:
• ASCT
Not suitable for transplant patients will continue accept treatment for 8 cycles.

Locations

Country	Name	City	State
China	Peking University People's Hospital, Institute of Hematology, Peking University	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking University People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete Response Rate		Up to cycle 4 (with 28 days per cycle).	No
Secondary	Safety	Safety evaluations will be based on scheduled clinical laboratory tests, electrocardiogram or cardiac ultrasonography (when appropriate), vital signs, physical examination and number of adverse events.	At baseline, on day 1 of each cycle, and after 4, 6, 12 and 18 months of follow-up.	Yes
Secondary	Overall Response Rate	Overall response rate included Complete Response (CR), Very good partial response (VGPR) and PR, before the new treatment, two consecutive evaluations are in line with defined criteria in order to confirm the efficacy evaluation.	At baseline, on day 28 of each cycle for 4 cycles.	No
Secondary	Time To Response		At baseline, on day 28 of each cycle for 4 cycles.	No
Secondary	1-year Survival Rate		At baseline, on day 28 of each cycle, and after 4, 6, 12 and 18 months of follow-up.	No
Secondary	Overall Survival		At baseline, on day 28 of each cycle, and after 4, 6, 12 and 18 months of follow-up.	No